前立腺における治療関連の変化:過去、現在、および将来の治療法
Katrina Collins1, Liang Cheng2
1Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Histopathology
|December 12, 2025
まとめ
病理学者は、ホルモン療法、放射線療法、および新しい侵襲的治療法を含む前立腺がん治療法が組織の組織学をどのように変化させるかを理解する必要があります。これらの変化を認識することは、前立腺がん検体の正確な診断とグレーディングに不可欠です。
科学分野:
- 尿生殖器病理学
- 腫瘍学
- 医学組織学
背景:
- 前立腺がんの管理には、確立された介入から新興のモダリティまで、さまざまな治療法が含まれます。
- アンドロゲン除去療法(ADT)や放射線療法(RT)などの治療法は、前立腺組織に顕著な組織学的変化を引き起こします。
- 新しいアブレーション技術がますます使用されていますが、その長期的な組織学的影響はさらに特徴付けられる必要があります。
研究 の 目的:
- 現在および調査中の前立腺がん治療法をレビューすること。
- これらの治療法が前立腺組織に及ぼす組織学的影響を説明すること。
- 治療後の前立腺検体を評価する病理学者へのガイダンスを提供すること。
主な方法:
- 前立腺がん治療法とその文書化された組織学的影響に関する文献レビュー。
- さまざまな治療後の良性および悪性前立腺組織の形態学的変化の分析。
- 治療後の設定における診断的解釈のための情報の統合。
主要な成果:
- 確立された治療法(根治的前立腺摘除術、ADT、RT)は、十分に文書化された広範な形態学的変化を引き起こします。
- 新興のアブレーション技術(凍結療法、HIFU、PDT、レーザー)も組織学的変化を引き起こしますが、これらはまだ特徴付けられています。
- 治療誘発性変化は、残存がんを不明瞭にし、グレーディング(例:Gleasonスコアリング)を複雑にし、病期分類の精度に影響を与える可能性があります。
結論:
- 病理学者は、前立腺検体における治療関連の組織学的変化のスペクトルを認識する必要があります。
- 正確な解釈には、臨床歴と観察された形態学的効果の統合が必要です。
- 前立腺がん病理学における診断精度の維持には、進化する治療法に関する情報を入手し続けることが不可欠です。
関連する概念動画
Disorders of the Male Reproductive System
3.9K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
529
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
529
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K


